Developer docs
API playgroundTry for free, no card

Search company profiles

Klea Holding

Full company profile

uuid002fioe

Namestring
Klea Holding
Legal namestring
Klea Holding
Websiteurl
kleaholding.com
Company typeenum
Public
Founded yearint
2007
Descriptiontext

Klea Holding is a Paris-headquartered international group (formerly Visiomed Group, founded 2007) listed on Euronext Growth Paris under ticker ALKLH. It operates through four healthcare subsidiaries centered on digital health delivery in the Gulf region: Smart Salem (wholly-owned digital medical testing centers in Dubai), Smart Health (a Saudi Arabia joint venture now majority-financed by Mobadara Investment), Klea Pharmaceuticals (a 46%-held subsidiary, with option to 70%, marketing licensed medicines across the Middle East and Africa), and Bewellthy (connected-health and telemedicine).

The core operating asset is the Smart Salem network of three DHA-accredited digital medical centers in Dubai (DIFC, Dubai Knowledge Park, and City Walk). These centers combine AI and virtual-reality-enabled diagnostics with structured medical analytics to screen for approximately 35 diseases — including HIV, hepatitis, and tuberculosis — in around 7 minutes, delivering visa-related medical fitness results in 30 minutes versus the 10–15 days reported at conventional providers. The group also markets VisioCheck, a sub-300g portable telemedicine station for healthcare professionals, and through Bewellthy offers teleconsultation, telemonitoring, and tele-expertise solutions.

Revenue is generated predominantly through per-test transactional fees — averaging AED 430 for visa-related medical fitness tests and AED 1,580 for premium Health & Wellness tests — at the three walk-in Dubai centers, supplemented by B2B corporate wellness engagement. Pharmaceutical distribution in the UAE is executed through a partnership with Al Khayyat Investments, providing access to 1,611 pharmacies and 51 hospital groups. FY2025 group revenue reached €22.2 million, with normalized EBITDA of €6.9 million (31% margin) and net financial debt of approximately €0.1 million, indicating a deleveraged, cash-generative operating model alongside active expansion into Saudi Arabia and pharmaceuticals.

Short descriptiontext

Klea Holding is a Paris-based international group operating Smart Salem, a network of DHA-accredited digital medical testing centers in Dubai, plus subsidiaries in Saudi Arabia (Smart Health), pharmaceuticals (Klea Pharmaceuticals), and telemedicine (Bewellthy), serving visa applicants and B2B clients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital medical diagnostics, visa medical fitness testing, connected health telemedicine, pharmaceutical distribution MEA, preventive health screening
Industry2 codes
1Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices)
CodeHLACAPAKPrimaryYes
2Pulmonary Function & Respiratory Diagnostic Centers (PFT/Spirometry)
CodeHLAFAKAJPrimaryNo
NAICS code2 codes
  • Medical and Diagnostic Laboratories62151
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Specialty Outpatient Facilities, Nec8093
Product category
Digital Medical Diagnostics & Healthcare Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Medical Fitness Testing Services
TypeTransaction Fee
Description

Revenue from medical fitness assessments required for residence and work visas in UAE. Smart Salem network performs health screenings and medical tests for visa purposes. Services are priced per test with volume growth driving revenue. Core business representing approximately 86% of 2025 revenue.

kleaholding.com
2Health & Wellness Testing
TypeTransaction Fee
Description

Preventive health check-ups and wellness testing services for individuals and corporate clients. Higher margin segment growing rapidly (153% growth in 2025 at constant exchange rates). Price increases implemented in H2 2025 reflecting high added value of offering.

kleaholding.com
3Pharmaceutical Product Sales
TypeLicensing Royalties
Description

Klea Pharmaceuticals subsidiary commercializing licensed medicines in Middle East and Africa. Initial portfolio of 57 medicines registered in UAE, targeting revenue of over AED 14.3 million (€3.9 million) by 2026, scaling to over AED 200 million (€50 million) by 2032.

kleaholding.com
4Connected Health Solutions
TypeHardware Sales
Description

Sale and deployment of VisioCheck telemedicine stations and related software solutions for telehealth use cases including teleconsultation, telemonitoring, and tele-expertise.

kleaholding.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
Pricing details2 tiers
1Medical Fitness Testing - Visa Health Assessment
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Average price of AED 430 per Medical Fitness test for visa purposes. Volume-based business with growth in test volumes driving revenue.

kleaholding.com
2Health & Wellness Premium Testing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Average price of AED 1,580 per Health & Wellness test (record September 2025). Price increases implemented in H2 2025 to reflect high added value of offering.

kleaholding.com
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 of 4 records shown
1Smart Salem
Description

Digitalized medical fitness testing centers accredited by Dubai Health Authority (DHA) offering medical fitness assessments, health & wellness tests

kleaholding.com
+3 more records
Core offering1 text field

Klea Holding operates digitalized medical testing centers through its Smart Salem subsidiary in Dubai, providing rapid medical fitness assessments required for UAE residence and work visas. The company detects approximately 35 diseases in 7 minutes using AI and advanced diagnostics, delivering visa medical clearance in 30 minutes versus 10-15 days at traditional health centers. It also offers premium health & wellness testing, telemedicine solutions via Bewellthy/VisioCheck, and pharmaceutical distribution in the Middle East and Africa via Klea Pharmaceuticals.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 30-minute visa medical clearance vs 10-15 days traditional
+4 more records
Product overview1 text field

Klea Holding is an international group operating a diversified healthcare portfolio through its subsidiaries. The core business is Smart Salem, a network of three digitalized medical testing centers in Dubai offering rapid Medical Fitness assessments for visa purposes. The company has expanded into Saudi Arabia through Smart Health joint venture and entered pharmaceuticals via Klea Pharmaceuticals subsidiary. Additionally, Bewellthy (resulting from BewellConnect/WCS merger) provides telemedicine solutions including VisioCheck portable stations. The group operates on a 'scaling industries of the future' model, leveraging AI and digital technologies across its healthcare services.

Product and service6 records
1Smart Salem Digital Medical Testing Centers
CategoryDigital medical diagnostics / Healthcare services
Description

Network of digitalized medical testing centers in Dubai (DIFC, Dubai Knowledge Park, City Walk) accredited by Dubai Health Authority. Uses AI and advanced diagnostics to detect ~35 diseases in 7 minutes and deliver visa medical fitness clearance in 30 minutes.

2Medical Fitness Assessment Service
CategoryDiagnostic healthcare service
Description

Rapid medical fitness assessment service for UAE visa applicants, screening for HIV, hepatitis, tuberculosis and other diseases. Delivers results in 30 minutes vs 10-15 days traditional. Approximately 86% of 2025 group revenue.

3Health & Wellness Tests
CategoryPreventive health & wellness service
Description

Premium preventive health check-up and wellness testing service for individuals and corporate clients. Higher-margin segment with 153% growth in 2025 at constant exchange rates.

4VisioCheck Telemedicine Station
CategoryConnected health hardware / telemedicine device
Description

Portable telemedicine station (under 300g) for healthcare professionals, available in case, station, or modular health space configurations. Supports teleconsultation, home telemonitoring, hospital monitoring, tele-expertise, teleassistance, and tele-regulation.

5Bewellthy Connected Health Platform
CategoryConnected health / telemedicine services
Description

Teleconsultation and connected health solutions platform combining medical devices and software for telehealth use cases including enriched assisted teleconsultation, telemonitoring, and tele-expertise.

6Klea Pharmaceuticals Licensed Medicines Portfolio
CategoryPharmaceutical distribution
Description

Marketing of licensed pharmaceutical products in Middle East and Africa markets. Initial portfolio of 57-59 medicines distributed via Al Khayyat Investments (AKI) covering 1,611 pharmacies (51% UAE) and 51 hospital groups. Target revenue AED 14.3 million by 2026, scaling to AED 200 million by 2032.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-11
Description

AKI is the pharmaceutical distribution partner for Klea Pharmaceuticals, providing nationwide coverage in UAE. Founded in 1965 with BinSina Pharmacy (first UAE pharmacy chain with 150+ pharmacies in UAE and Oman). AKI Healthcare division holds over 4% market share in Middle East pharmaceutical distribution (15%+ in UAE). Offers integrated logistics, regulatory excellence, and 100% cold chain control. Distribution network covers 1,611 pharmacies (51% UAE) and 51 hospital groups.

2Klea Pharmaceuticals Co-Founders
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-01
Description

Two founders from international pharmaceutical industry holding stake alongside Klea Holding (46% initial, option to increase to 70% within three years). Founders bring significant expertise in development, registration and commercialization of pharmaceutical products in Middle East, Africa and Europe.

kleaholding.com
Strategic tierSupportingTypeTechnology or IntegrationAnnounced on2026-04-01
Description

18 international production sites, all US FDA or EU GMP-certified, for outsourced pharmaceutical manufacturing. Industrial model for Klea Pharmaceuticals product supply.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-31
Description

New shareholder joining Smart Health to unlock potential in Saudi Arabia. Shareholder agreement where most future Capex & Opex will be covered by Mobadara Investment. Partnership enables Smart Health development in KAFD, Riyadh. Majority control transferred to Mobadara, with Klea Holding changing consolidation method from full consolidation to equity method.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-02-17
Description

Two powerful partners for entering Saudi market. Joint venture Smart Health dedicated to deploying digital medical testing centers in Saudi Arabia. Incorporation completed September 2023.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-01-11
Description

WCS merged with BewellConnect subsidiary to form Bewellthy, combining telemedicine and connected health solutions capabilities. Strategic consolidation of telehealth offerings.

Recent move13 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

UAE-headquartered healthcare conglomerate with hospitals, clinics and pharmacies across the Middle East and India. Comparable geographic footprint in the Gulf healthcare market with similar regulatory positioning in UAE and Saudi Arabia.

TypeDirect peer
Description

Europe's largest medical diagnostics services provider operating centralized laboratory networks. Comparable to Klea in the diagnostics-services layer, though Synlab's model is centralized lab vs Klea's distributed digital center network.

TypeEmerging player
Description

European digital health platform for appointment booking and teleconsultation. Comparable in digital health patient experience and consumer-facing healthcare delivery, with overlapping connected-health ambitions.

TypeBroad incumbent
Description

Largest US clinical laboratory company providing diagnostic testing services. Relevant comparable as a scaled diagnostics platform, though focused on routine clinical lab testing rather than consumer-facing medical fitness assessments.

TypeRegional player
Description

UAE-based healthcare provider operating diagnostic centers and clinics across the Gulf. Comparable in operating physical diagnostic and clinical service locations in the same UAE market where Smart Salem competes.

TypeEmerging player
Description

Global leader in telemedicine and virtual care delivery. Comparable to Klea's Bewellthy/VisioCheck connected-health platform in the telemedicine delivery layer, though at vastly different scale and consumer vs enterprise orientation.

TypeBroad incumbent
Description

Global diagnostics provider with extensive laboratory networks across Australia, Europe and the US. Comparable in operating model (high-volume diagnostic testing at scale) and in the breadth of routine and specialty testing menus.

TypeEmerging player
Description

US occupational health and pre-employment medical testing network. Comparable in the dedicated employment/visa medical fitness testing niche that drives ~86% of Klea's revenue, though operating in a different regulatory and payment environment.

TypeBroad incumbent
Description

Largest private healthcare provider in the UAE with hospitals, clinics and diagnostic services. Operates in the same UAE healthcare market with overlapping diagnostic and outpatient capabilities, though broader in scope (inpatient hospital focus).

TypeRegional player
Description

Leading Middle East medical laboratory chain headquartered in Saudi Arabia. Comparable as a regional diagnostics services provider with overlapping Gulf market footprint and similar test-menu breadth.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Klea Holding

Digital Medical Diagnostics & Healthcare Serviceskleaholding.com

Klea Holding is a Paris-based international group operating Smart Salem, a network of DHA-accredited digital medical testing centers in Dubai, plus subsidiaries in Saudi Arabia (Smart Health), pharmaceuticals (Klea Pharmaceuticals), and telemedicine (Bewellthy), serving visa applicants and B2B clients.

What Klea Holding does

Klea Holding is a Paris-headquartered international group (formerly Visiomed Group, founded 2007) listed on Euronext Growth Paris under ticker ALKLH. It operates through four healthcare subsidiaries centered on digital health delivery in the Gulf region: Smart Salem (wholly-owned digital medical testing centers in Dubai), Smart Health (a Saudi Arabia joint venture now majority-financed by Mobadara Investment), Klea Pharmaceuticals (a 46%-held subsidiary, with option to 70%, marketing licensed medicines across the Middle East and Africa), and Bewellthy (connected-health and telemedicine).

The core operating asset is the Smart Salem network of three DHA-accredited digital medical centers in Dubai (DIFC, Dubai Knowledge Park, and City Walk). These centers combine AI and virtual-reality-enabled diagnostics with structured medical analytics to screen for approximately 35 diseases — including HIV, hepatitis, and tuberculosis — in around 7 minutes, delivering visa-related medical fitness results in 30 minutes versus the 10–15 days reported at conventional providers. The group also markets VisioCheck, a sub-300g portable telemedicine station for healthcare professionals, and through Bewellthy offers teleconsultation, telemonitoring, and tele-expertise solutions.

Revenue is generated predominantly through per-test transactional fees — averaging AED 430 for visa-related medical fitness tests and AED 1,580 for premium Health & Wellness tests — at the three walk-in Dubai centers, supplemented by B2B corporate wellness engagement. Pharmaceutical distribution in the UAE is executed through a partnership with Al Khayyat Investments, providing access to 1,611 pharmacies and 51 hospital groups. FY2025 group revenue reached €22.2 million, with normalized EBITDA of €6.9 million (31% margin) and net financial debt of approximately €0.1 million, indicating a deleveraged, cash-generative operating model alongside active expansion into Saudi Arabia and pharmaceuticals.

Klea Holding firmographics

Firmographics
Name
Klea Holding
Legal name
Klea Holding
Website
https://kleaholding.com
Company type
Public
Founded year
2007
Operating status
Operating
Headcount range
51–100 employees
Short description
Klea Holding is a Paris-based international group operating Smart Salem, a network of DHA-accredited digital medical testing centers in Dubai, plus subsidiaries in Saudi Arabia (Smart Health), pharmaceuticals (Klea Pharmaceuticals), and telemedicine (Bewellthy), serving visa applicants and B2B clients.
Ownership category
akta.pro rank

Klea Holding industry classification

Industry
Product category
Digital Medical Diagnostics & Healthcare Services
NAICS
Medical and Diagnostic Laboratories (62151), Medical and Diagnostic Laboratories (6215)
SIC
Services-Medical Laboratories (8071), Services-Specialty Outpatient Facilities, Nec (8093)
akta.pro primary industry
Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK)
akta.pro secondary industry
Pulmonary Function & Respiratory Diagnostic Centers (PFT/Spirometry) (HLAFAKAJ)

Keywords

  • Digital medical diagnostics
  • Visa medical fitness testing
  • Connected health telemedicine
  • Pharmaceutical distribution MEA
  • Preventive health screening

Where Klea Holding is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices4 records

Markets served

Klea Holding business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Medical Fitness Testing Services: Revenue from medical fitness assessments required for residence and work visas in UAE. Smart Salem network performs health screenings and medical tests for visa purposes. Services are priced per test with volume growth driving revenue. Core business representing approximately 86% of 2025 revenue.
  2. Health & Wellness Testing: Preventive health check-ups and wellness testing services for individuals and corporate clients. Higher margin segment growing rapidly (153% growth in 2025 at constant exchange rates). Price increases implemented in H2 2025 reflecting high added value of offering.
  3. Pharmaceutical Product Sales: Klea Pharmaceuticals subsidiary commercializing licensed medicines in Middle East and Africa. Initial portfolio of 57 medicines registered in UAE, targeting revenue of over AED 14.3 million (€3.9 million) by 2026, scaling to over AED 200 million (€50 million) by 2032.
  4. Connected Health Solutions: Sale and deployment of VisioCheck telemedicine stations and related software solutions for telehealth use cases including teleconsultation, telemonitoring, and tele-expertise.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goMedical Fitness Testing - Visa Health Assessment
Unit PricingPay-as-you-goHealth & Wellness Premium Testing

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Klea Holding product offering

Product offering

Core offering

Klea Holding operates digitalized medical testing centers through its Smart Salem subsidiary in Dubai, providing rapid medical fitness assessments required for UAE residence and work visas. The company detects approximately 35 diseases in 7 minutes using AI and advanced diagnostics, delivering visa medical clearance in 30 minutes versus 10-15 days at traditional health centers. It also offers premium health & wellness testing, telemedicine solutions via Bewellthy/VisioCheck, and pharmaceutical distribution in the Middle East and Africa via Klea Pharmaceuticals.

Product overview

Klea Holding is an international group operating a diversified healthcare portfolio through its subsidiaries. The core business is Smart Salem, a network of three digitalized medical testing centers in Dubai offering rapid Medical Fitness assessments for visa purposes. The company has expanded into Saudi Arabia through Smart Health joint venture and entered pharmaceuticals via Klea Pharmaceuticals subsidiary. Additionally, Bewellthy (resulting from BewellConnect/WCS merger) provides telemedicine solutions including VisioCheck portable stations. The group operates on a 'scaling industries of the future' model, leveraging AI and digital technologies across its healthcare services.

Differentiator

Problem solved

Functional benefit

Brands

  • Smart Salem: Digitalized medical fitness testing centers accredited by Dubai Health Authority (DHA) offering medical fitness assessments, health & wellness tests
  • Smart Health
  • Bewellthy
  • Klea Pharmaceuticals

Products and services

  • Smart Salem Digital Medical Testing Centers Network of digitalized medical testing centers in Dubai (DIFC, Dubai Knowledge Park, City Walk) accredited by Dubai Health Authority. Uses AI and advanced diagnostics to detect ~35 diseases in 7 minutes and deliver visa medical fitness clearance in 30 minutes.
  • Medical Fitness Assessment Service Rapid medical fitness assessment service for UAE visa applicants, screening for HIV, hepatitis, tuberculosis and other diseases. Delivers results in 30 minutes vs 10-15 days traditional. Approximately 86% of 2025 group revenue.
  • Health & Wellness Tests Premium preventive health check-up and wellness testing service for individuals and corporate clients. Higher-margin segment with 153% growth in 2025 at constant exchange rates.
  • VisioCheck Telemedicine Station Portable telemedicine station (under 300g) for healthcare professionals, available in case, station, or modular health space configurations. Supports teleconsultation, home telemonitoring, hospital monitoring, tele-expertise, teleassistance, and tele-regulation.
  • Bewellthy Connected Health Platform Teleconsultation and connected health solutions platform combining medical devices and software for telehealth use cases including enriched assisted teleconsultation, telemonitoring, and tele-expertise.
  • Klea Pharmaceuticals Licensed Medicines Portfolio Marketing of licensed pharmaceutical products in Middle East and Africa markets. Initial portfolio of 57-59 medicines distributed via Al Khayyat Investments (AKI) covering 1,611 pharmacies (51% UAE) and 51 hospital groups. Target revenue AED 14.3 million by 2026, scaling to AED 200 million by 2032.

Quantifiable outcome

  • 30-minute visa medical clearance vs 10-15 days traditional
  • +4 more outcomes

Companies that use Klea Holding

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Klea Holding technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature3 records

Klea Holding partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core, supporting and minor.

  • Al Khayyat Investments (AKI)coreChannel Partner/ Reseller/ Distributor · 11 June 2026AKI is the pharmaceutical distribution partner for Klea Pharmaceuticals, providing nationwide coverage in UAE. Founded in 1965 with BinSina Pharmacy (first UAE pharmacy chain with 150+ pharmacies in UAE and Oman). AKI Healthcare division holds over 4% market share in Middle East pharmaceutical distribution (15%+ in UAE). Offers integrated logistics, regulatory excellence, and 100% cold chain control. Distribution network covers 1,611 pharmacies (51% UAE) and 51 hospital groups.
  • Klea Pharmaceuticals Co-FounderscoreStrategic or Co-development Partner · 1 April 2026Two founders from international pharmaceutical industry holding stake alongside Klea Holding (46% initial, option to increase to 70% within three years). Founders bring significant expertise in development, registration and commercialization of pharmaceutical products in Middle East, Africa and Europe.
  • CDMOs (Contract Development and Manufacturing Organisations)supportingTechnology or Integration · 1 April 202618 international production sites, all US FDA or EU GMP-certified, for outsourced pharmaceutical manufacturing. Industrial model for Klea Pharmaceuticals product supply.
  • Mobadara InvestmentcoreStrategic or Co-development Partner · 31 March 2025New shareholder joining Smart Health to unlock potential in Saudi Arabia. Shareholder agreement where most future Capex & Opex will be covered by Mobadara Investment. Partnership enables Smart Health development in KAFD, Riyadh. Majority control transferred to Mobadara, with Klea Holding changing consolidation method from full consolidation to equity method.
  • Smart Health Saudi Arabia PartnerscoreStrategic or Co-development Partner · 17 February 2023Two powerful partners for entering Saudi market. Joint venture Smart Health dedicated to deploying digital medical testing centers in Saudi Arabia. Incorporation completed September 2023.
  • Whealthy Care Solutions (WCS)minorStrategic or Co-development Partner · 11 January 2023WCS merged with BewellConnect subsidiary to form Bewellthy, combining telemedicine and connected health solutions capabilities. Strategic consolidation of telehealth offerings.

Scale indicators10 records

Recent moves13 records

Expansion highlights6 records

Klea Holding competitors and assessment

Company assessment

Broad incumbents

  • Aster DM Healthcare: UAE-headquartered healthcare conglomerate with hospitals, clinics and pharmacies across the Middle East and India. Comparable geographic footprint in the Gulf healthcare market with similar regulatory positioning in UAE and Saudi Arabia.
  • Quest Diagnostics: Largest US clinical laboratory company providing diagnostic testing services. Relevant comparable as a scaled diagnostics platform, though focused on routine clinical lab testing rather than consumer-facing medical fitness assessments.
  • Sonic Healthcare: Global diagnostics provider with extensive laboratory networks across Australia, Europe and the US. Comparable in operating model (high-volume diagnostic testing at scale) and in the breadth of routine and specialty testing menus.
  • NMC Healthcare: Largest private healthcare provider in the UAE with hospitals, clinics and diagnostic services. Operates in the same UAE healthcare market with overlapping diagnostic and outpatient capabilities, though broader in scope (inpatient hospital focus).

Direct peers

  • Synlab: Europe's largest medical diagnostics services provider operating centralized laboratory networks. Comparable to Klea in the diagnostics-services layer, though Synlab's model is centralized lab vs Klea's distributed digital center network.

Emerging players

  • Doctolib: European digital health platform for appointment booking and teleconsultation. Comparable in digital health patient experience and consumer-facing healthcare delivery, with overlapping connected-health ambitions.
  • Teladoc Health: Global leader in telemedicine and virtual care delivery. Comparable to Klea's Bewellthy/VisioCheck connected-health platform in the telemedicine delivery layer, though at vastly different scale and consumer vs enterprise orientation.
  • Concentra Group: US occupational health and pre-employment medical testing network. Comparable in the dedicated employment/visa medical fitness testing niche that drives ~86% of Klea's revenue, though operating in a different regulatory and payment environment.

Regional players

  • Gulf Healthcare International: UAE-based healthcare provider operating diagnostic centers and clinics across the Gulf. Comparable in operating physical diagnostic and clinical service locations in the same UAE market where Smart Salem competes.
  • Al Borg Medical Laboratories: Leading Middle East medical laboratory chain headquartered in Saudi Arabia. Comparable as a regional diagnostics services provider with overlapping Gulf market footprint and similar test-menu breadth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Klea Holding social profiles

Digital presence

Klea Holding compliance and trust

Trust signal

Compliance4 records

Klea Holding financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Klea Holding leadership team

Management profile

Number of profiles

Profiles7 records

Klea Holding subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Klea Holding funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Klea Holding M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Klea Holding

What does Klea Holding do?

Klea Holding operates digitalized medical testing centers through its Smart Salem subsidiary in Dubai, providing rapid medical fitness assessments required for UAE residence and work visas. The company detects approximately 35 diseases in 7 minutes using AI and advanced diagnostics, delivering visa medical clearance in 30 minutes versus 10-15 days at traditional health centers. It also offers premium health & wellness testing, telemedicine solutions via Bewellthy/VisioCheck, and pharmaceutical distribution in the Middle East and Africa via Klea Pharmaceuticals.

Is Klea Holding a public or private company?

Klea Holding is a public company. It is classified as public and is currently operating.

When was Klea Holding founded?

Klea Holding was founded in 2007. It employs 51 to 100 people.

Where is Klea Holding based?

Klea Holding is headquartered in Paris, France, in the Europe region.

How does Klea Holding make money?

Four revenue lines are on record. Medical Fitness Testing Services are the primary driver. The others are health & Wellness Testing, pharmaceutical Product Sales and connected Health Solutions.

Who are Klea Holding's main competitors?

Broad incumbents on record are Aster DM Healthcare, Quest Diagnostics, Sonic Healthcare and NMC Healthcare. Synlab is listed as a direct peer. Emerging players are Doctolib, Teladoc Health and Concentra Group. Regional players are Gulf Healthcare International and Al Borg Medical Laboratories.

Does Klea Holding have an API?

No public API is recorded for Klea Holding.

What industry is Klea Holding in?

Klea Holding's product category is Digital Medical Diagnostics & Healthcare Services. Its primary akta.pro industry code is HLACAPAK, Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices), with a secondary code of HLAFAKAJ, Pulmonary Function & Respiratory Diagnostic Centers (PFT/Spirometry). Its NAICS code is 62151 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinancialContent Business PageKlea Holding confirme son rebond progressif au 3ème trimestre 2026 et vise une croissance des ventes au 4ème trimestre 2026Klea Holding reported unaudited third-quarter 2026 revenue of €4.4 million, down 15% year-over-year, with its Smart Salem subsidiary's wellness segment driving growth. The company expects a sales rebound in Q4 2026 from the launch of Klea Health and Klea Pharmaceuticals, targeting a net profit at least equal to 2025.FinancialContent Business PageKlea Holding confirms its gradual rebound in Q3 2026 and targets revenue growth in Q4 2026Klea Holding reported Q3 2026 revenue of €4.4 million, down 15% at constant exchange rates from €5.1 million in Q3 2025. The group expects a return to growth in Q4 2026, driven by Klea Health and Klea Pharmaceuticals, targeting over €2 million in profitable revenue from the latter by year-end.FinancialContent Business PageKLEA HOLDING : Déclaration des transactions sur actions propresKLEA HOLDING declared its own share purchases under MAR Article 5, buying 165,000 shares on 29 September and 85,000 on 28 September at average prices of 0.13 and 0.134 euros, respectively. The company, based in Paris and listed on Euronext Growth, operates in medical analysis centers and pharmaceuticals in the Middle East and Africa.FinancialContent Business PageKLEA HOLDING : Déclaration des transactions sur actions propresKLEA HOLDING declared its own share purchases under MAR Article 5 on September 21-24, 2026, on Euronext Paris. The purchases totaled 259,000 shares at weighted average prices between €0.138 and €0.141. The company, based in Paris, operates in the Middle East and Africa.FinancialContent Business PageKLEA HOLDING : Toujours rentable au 1er semestre 2026, Klea Holding investit dans ses futurs moteurs de croissanceKlea Holding reported H1 2026 revenue of 8.6M€ and net profit of 0.3M€, down 25% and 69% respectively, due to Middle East conflict. The group maintained profitability with EBITDA of 1.6M€ and 2.2M€ normalized, and plans to open Smart Santé and launch Klea Pharmaceuticals.FinancialContent Business PageKLEA HOLDING : Still profitable in H1 2026, Klea Holding invests in its future growth driversKlea Holding reported first-half 2026 revenue of €8.6 million, down 25% year-on-year, but remained profitable with net profit of €0.3 million. The group launched Klea Pharmaceuticals and Smart Health, and reaffirmed its target of another profitable year in 2026.FinancialContent Business PageKLEA HOLDING : Déclaration des transactions sur actions propresKLEA HOLDING declared its own share purchases under MAR Article 5 on September 7, 9, and 11, 2026. The purchases totaled 2,011,000 shares at weighted average prices of 0.146, 0.141, and 0.162 euros, respectively, on Euronext Paris.FinancialContent Business PageKlea Holding provides an update on the imminent launch of its operations in Saudi ArabiaKlea Holding's subsidiary Smart Health has completed construction and site development for its first digital medical centre in Riyadh, Saudi Arabia, funded internally. The company is awaiting final regulatory approval from the Civil Protection Authority, with opening expected in a few weeks.FinancialContent Business PageKlea Holding fait un point d'avancement sur le démarrage prochain de son activité en Arabie SaouditeKlea Holding's Smart Health subsidiary has completed construction of its first digital medical center in Riyadh, Saudi Arabia, funded entirely from internal resources. The company is awaiting final regulatory approvals, including a civil protection clearance, with an opening expected within weeks.FinancialContent Business PageKLEA HOLDING : Déclaration des transactions sur actions propresKLEA HOLDING declared a purchase of its own shares on 28 August 2026, acquiring 115,000 shares at an average price of €0.151 on the Paris stock exchange. The company, based in Paris and listed on Euronext Growth, operates in medical analysis centers and pharmaceuticals in the Middle East and Africa.